A radiogenomic model based on 18F-FDG PET/CT radiomics and clinical EGFR has good application value in predicting PFS stratification of lung-cancer patients after SBRT treatment, which can provide a reference to clinical medicine. This evidence concerns the gene EGFR and lung cancer.